Aug 28, 2026Priovant receives first FDA approval for targeted tablet in dermatomyositisPriovant Therapeutics secured its first FDA approval for a targeted tablet treatment for dermatomyositis, a rare autoimmune disease affecting muscles and skin.Aug 28, 2026·2 sources00
